


Inventions represented at Danish IP Fair 2018

This document contains one-pagers for all inventions within **Biotech and Pharma** presented at the Danish IP Fair 2018. You can use this document to identify meeting partners at the event. Each invention is marked with a unique ID at the top right of the page. Use this ID to look up and book a meeting with the inventor(s) at the Danish IP Fair website - www.dipfair.dk.

The document will be updated regularly in the period February-April, so ensure to re-visit the website for the newest version.

For further guidelines regarding meeting bookings please consult the menu Matchmaking on the website.

Compounds towards novel treatments for infertility



Value Proposition/USP

The technology allow for control of the most important early step of egg regulation via. either activation or maintenance of dormancy.

Business Opportunity/Objective/Commercial Perspectives

Present invention will make it possible to activate the resting (primordial) follicles, allowing a more effective treatment of infertility than what is possible with current commercial solutions. This could in particular help the increasing group of women with age-related decline in eggs and/or women categorized as 'low responders', who does not respond to todays treatment aiming at the later follicle stages. The invention also allows for holding back egg maturation, thereby protecting the pool of resting eggs, i.e. the reproductive potential, from premature expiration.

Technology Description/Technology Summary

Aarhus University have invented a list of new factors for screening for compounds that regulates early ovarian follicle maturation. We already identified compounds that hold promise for treating, preventing or ameliorating infertility in a large increasing cohort of women not responding to current available fertility treatments. Additional compounds are expected to be identifiable through an *in vitro*-based screening method.

Development Phase/Current State

Proof-of-concept has been provided using *in vitro* primary culture of mouse ovaries as model system. Soft funding has been secured for testing of the identified compounds, which are currently ongoing.

The inventors

Karin Lykke-Hartmann, Associate professor
Emil Hagen Ernst, Medical Doctor, PhD
Anders Heuck, Laboratory Technician

Contact Information

Morten Holmager
Business Development Manager
+45 9350 8718
holmager@au.dk

Seeking


- Funding/Investors
- Licensee
- Partner/Research Collaboration

The technology is protected through European patent applications EP17173965.9 filled in June 2017 and 17209250.4 filled in December 2017.

pDC BioTech ApS – enabling high-volume supply of plasmacytoid dendritic cells!

Contract Research Organisation

Strategy to develop business model towards a therapeutic approach to Oncology & Lupus



Anders Laustsen



Martin Jakobsen

BUSINESS MODEL

TECHNOLOGY

TEAM

Value Proposition

The biopharma industry needs a superior supply of plasmacytoid dendritic cells. These cells are needed as they have been linked to a number of diseases, including Systemic Lupus Erythmatosus and cancer. However, only limited quantities of these cells can be isolated from human blood or tissues.

“pDC Biotech” – a prospective startup company - seeks to meet this need through a technology that allows pDCs to be generated at high numbers. Our strategy is to build early-financing on a CRO business model and develop an *ex-vivo* therapeutic approach in Oncology.

Business Opportunity

pDC Biotech is currently designing feasibility studies with a number of biopharma companies to benchmark the technology and demonstrate how they compare to pDCs isolated directly from human blood. The company believes that these early feasibility studies will demonstrate the commercial value of the technology. The company will then employ sales staff and transition to a direct sales supply and consultancy service to the Biopharma industry.

Technology Summary

Research within pDC biology has so far been non-conceivable owing to the rarity of the cell type within blood. Our technology utilizes stem cells that are expanded under specific growth conditions. This has not only allowed us to generate high numbers of pDCs, but as the stem cells are readily amenable to genetic modification, we can generate genetically modified pDCs, allowing researchers to elucidate specific molecular pathways in pDCs.

Current State

As stem cells can be derived from patient, our technology allow patient-derived pDCs to be generated. We are therefore currently investigating the feasibility of utilizing stem-cell derived pDCs to guide specific immune responses. As an initial study we wish to investigate their potential to induce specific anti-tumoral responses. We believe that our method has high potential within clinical immune-therapy where patient-derived pDCs are used to attack the tumor with minimal adverse effects.

The inventors

Anders Laustsen, PhD
Martin Jakobsen, PhD, Associate Professor

Contact Information

Eoin Galligan,
Business Development Manager
ega@au.dk

Seeking

Partnering discussions related to feasibility studies and future sales

The technology has been described in a 2017 European patent application (EP17170373.9) and is pending.